T Preijers1, I van Moort2, K Fijnvandraat3, F W G Leebeek4, M H Cnossen2, R A A Mathôt1. 1. Department of Clinical Pharmacology, Hospital Pharmacy-Clinical Pharmacology, Academic Medical Center, Amsterdam, The Netherlands. 2. Department of Pediatric Hematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Department of Pediatric Hematology, Academic Medical Center, Amsterdam, The Netherlands. 4. Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Abstract
BACKGROUND: Patients with severe and moderate haemophilia A are treated prophylactically with factor VIII (FVIII) concentrate. Individualization of prophylaxis can be achieved by pharmacokinetic (PK)-guided dosing. AIM: In this study, the performance of three PK tools (myPKFiT, Web-Accessible Population Pharmacokinetic Service-Hemophilia [WAPPS] and NONMEM) is compared. METHODS: In 39 patients, with severe or moderate haemophilia A, blood samples were collected 4, 24 and 48 hours after administration of 50 IU kg-1 of recombinant FVIII (Advate [n = 30] or Kogenate [n = 9]). FVIII dose, FVIII activity and patient characteristics were entered into the three PK tools. Obtained PK parameters and dosing advises were compared. RESULTS: myPKFiT provided PK parameters for 24 of 30 patients receiving Advate, whereas WAPPS and NONMEM provided estimates for all patients. Half-life was different among the three methods: medians were 12.6 hours (n = 24), 11.2 hours (n = 30) and 13.0 hours (n = 30) for myPKFiT, WAPPS and NONMEM (p < 0.001), respectively. To maintain a FVIII trough level of 0.01 IU mL-1 after 48 hours, doses for myPKFiT and NONMEM were 15.1 and 11.0 IU kg-1 (p < 0.01, n = 11) and for WAPPS and NONMEM were 9.0 and 8.0 IU kg-1 (p < 0.01, n = 23), respectively. In nine patients receiving Kogenate, WAPPS and NONMEM produced different PK-parameter estimates; half-life was 15.0 and 12.3 hours and time to 0.05 IU mL-1 was 69.2 and 60.8 hours, respectively (p < 0.01, n = 9). However, recommended doses to obtain these levels were not different. CONCLUSION: The three evaluated PK tools produced different PK parameters and doses for recombinant FVIII. Haematologists should be aware that recommended doses may be influenced by the choice of PK tool. Schattauer GmbH Stuttgart.
BACKGROUND:Patients with severe and moderate haemophilia A are treated prophylactically with factor VIII (FVIII) concentrate. Individualization of prophylaxis can be achieved by pharmacokinetic (PK)-guided dosing. AIM: In this study, the performance of three PK tools (myPKFiT, Web-Accessible Population Pharmacokinetic Service-Hemophilia [WAPPS] and NONMEM) is compared. METHODS: In 39 patients, with severe or moderate haemophilia A, blood samples were collected 4, 24 and 48 hours after administration of 50 IU kg-1 of recombinant FVIII (Advate [n = 30] or Kogenate [n = 9]). FVIII dose, FVIII activity and patient characteristics were entered into the three PK tools. Obtained PK parameters and dosing advises were compared. RESULTS: myPKFiT provided PK parameters for 24 of 30 patients receiving Advate, whereas WAPPS and NONMEM provided estimates for all patients. Half-life was different among the three methods: medians were 12.6 hours (n = 24), 11.2 hours (n = 30) and 13.0 hours (n = 30) for myPKFiT, WAPPS and NONMEM (p < 0.001), respectively. To maintain a FVIII trough level of 0.01 IU mL-1 after 48 hours, doses for myPKFiT and NONMEM were 15.1 and 11.0 IU kg-1 (p < 0.01, n = 11) and for WAPPS and NONMEM were 9.0 and 8.0 IU kg-1 (p < 0.01, n = 23), respectively. In nine patients receiving Kogenate, WAPPS and NONMEM produced different PK-parameter estimates; half-life was 15.0 and 12.3 hours and time to 0.05 IU mL-1 was 69.2 and 60.8 hours, respectively (p < 0.01, n = 9). However, recommended doses to obtain these levels were not different. CONCLUSION: The three evaluated PK tools produced different PK parameters and doses for recombinant FVIII. Haematologists should be aware that recommended doses may be influenced by the choice of PK tool. Schattauer GmbH Stuttgart.
Authors: Susan M Abdel-Rahman; Harpreet Gill; Shannon L Carpenter; Pathe Gueye; Brian Wicklund; Matt Breitkreutz; Arindam Ghosh; Avinash Kollu Journal: Appl Clin Inform Date: 2020-04-08 Impact factor: 2.342
Authors: T Preijers; M W F van Spengler; K Meijer; K Fijnvandraat; K Fischer; F W G Leebeek; M H Cnossen; R A A Mathôt Journal: Eur J Clin Pharmacol Date: 2021-10-15 Impact factor: 2.953
Authors: Tim Preijers; Lisette M Schütte; Marieke J H A Kruip; Marjon H Cnossen; Frank W G Leebeek; Reinier M van Hest; Ron A A Mathôt Journal: Clin Pharmacokinet Date: 2021-01 Impact factor: 6.447
Authors: Tim Preijers; Ri Liesner; Hendrika C A M Hazendonk; Pratima Chowdary; Mariëtte H E Driessens; Dan P Hart; Britta A P Laros-van Gorkom; Felix J M van der Meer; Karina Meijer; Karin Fijnvandraat; Frank W G Leebeek; Ron A A Mathôt; Marjon H Cnossen Journal: Br J Clin Pharmacol Date: 2021-05-04 Impact factor: 4.335
Authors: Lars L F G Valke; Laura H Bukkems; Wideke Barteling; Britta A P Laros-van Gorkom; Nicole M A Blijlevens; Ron A A Mathôt; Waander L van Heerde; Saskia E M Schols Journal: J Thromb Haemost Date: 2020-10-21 Impact factor: 16.036